Gelonghui, April 25 | AstraZeneca (AZN.US) rose nearly 6% to US$75.35 before the market opened.
On the news, the company\’s pre-market results showed that Q1 total revenue was US$12.679 billion, a year-on-year increase of 19%, which was better than market expectations of US$11.84 billion; core earnings per share was US$2.06, a year-on-year increase of 13%, which was also better than the market. Expected $1.92.
During the period, product sales revenue reached US$12.177 billion, a year-on-year increase of 18%, and the gross profit margin of core product sales was 82%.
Among them, the oncology business performed strongly, with sales of US$5.108 billion, a year-on-year increase of 26%; the CVRM (cardiovascular, renal disease, metabolism) business sales were US$3.06 billion, a year-on-year increase of 23%.
AstraZeneca rose nearly 6% before the market opened, Q1 results exceeded expectations
Gelonghui, April 25 | AstraZeneca (AZN.US) rose nearly 6% to US$75.35 before the market opened. On the news, the company\’s pre-market results showed that Q1 total revenue was US$12.679 billion, a year-on-year increase of 19%, which was better than market expectations of US$11.84 billion; core earnings per share was US$2.06, a year-on-year increase of 13%, which was also better than the market. Expected $1.92.
Like (0)
Gree: The recent article online that Dong Mingzhu ordered the dismissal of an employee is purely false.
Previous
April 25, 2024 5:04 pm
Nissan (China) and Baidu sign cooperation memorandum of understanding
Next
April 25, 2024 5:04 pm